FDA warns J & J on insulin pumps

Share this article:

Johnson & Johnson could face penalties for not reporting incidents where insulin pumps have failed, the Food and Drug Administration has warned.

In a Dec. 27 letter to the company's Animas Corp. unit, the FDA says the company should have reported incidents where the device failure may have caused injury, including diabetic ketoacidosis. It also said Animas failed to create a system for making adequate medical device reports.

The letter, which was made public last week, followed a site visit in 2011. It warns “failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice.”

Diabetes is among the top ten leading causes of death in the U.S. Insulin pumps deliver rapid- or short-acting insulin throughout the day via a catheter rather than require a person or caregiver to do periodic injections.



Share this article:

More in News

Nursing home antipsychotic use has dipped nearly 19% under national effort, latest figures show

Nursing home antipsychotic use has dipped nearly 19% ...

The percent of long-stay nursing home residents receiving antipsychotic medication has decreased 18.8% under a nationwide initiative that started in 2012, according to the most recent quarterly figures from the ...

Jimmo succeeds in getting Medicare coverage, two years after landmark case ended

Glenda Jimmo has reached a settlement with the federal government and will finally receive Medicare coverage for claims that were denied in 2007, which led her to file a class-action lawsuit over the so-called "improvement standard."

Also in the news for Oct. 31, 2014 . . .

Minnix hopes White House aging conference will spur 'huge shift' ... CMS finalizes home health payment reductions ... Dementia is now No. 1 killer of women in England